The European Medicines Agency inspection supports renewal of GMP certificate at pharmaceutical analytical testing and development site.

The expansion in Visp will now include three multiproduct suites, with commercial manufacturing capacity expected to be operational from 2028.

Haverhill’s new spray dryer, slated to become available in the last quarter of 2027, will expand solvent-based capacity for amorphous solid dispersions.

CARR’s single-use centrifugation platform will support process volumes from milliliters to more than 2,000 liters, according to the companies.

The agreement assigns recombinant human apoA-I purification to Axplora’s site in France, completing the planned manufacturing network.

The equipment will help formulation scientists assess scale-up risks using small quantities of active pharmaceutical ingredients before commercial manufacturing.

The Valladolid expansion will add capacity for steroid and non-steroid active pharmaceutical ingredients, supporting complex sterile formulations and production.

The expanded BARDA deal adds approximately $270 million in procurement through 2031 as the company advances an investigational antibody against another Ebola virus species.